Garveatin E | 873536-71-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: Garveatin E
• 英文别名: 3-ethyl-7,10-dihydroxy-2,6,8,8-tetramethyl-1,4,5,8-tetrahydroanthracene-1,4,5-trione
• CAS: 873536-71-1
• 化学式: C20H20O5
• InChiKey: CXDZOCPWVKOLAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  91.67
• 氢给体数：
  2.0
• 氢受体数：
  5.0

文献信息

• Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer
  申请人：THE UNIVERSITY OF BRITISH COLUMBIA

  公开号：EP2130826A1

  公开（公告）日：2009-12-09

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cancer. IDO inhibitors of this invention are homologs of annulin A, annulin B or annulin C.

  本研究提供了吲哚胺 2,3-二氧化酶（IDO）的抑制剂以及含有此类抑制剂的药物组合物，还提供了使用此类抑制剂和组合物治疗哺乳动物体内以 IDO 介导的色氨酸代谢途径病理学为特征的疾病的方法。此类病症可能涉及抑制 T 细胞介导的免疫反应，也可能直接导致色氨酸耗竭或色氨酸降解产物的积累。具体的疾病情况包括癌症。本发明的 IDO 抑制剂是鹅膏素 A、鹅膏素 B 或鹅膏素 C 的同源物。
• Indoleamine 2,3-Dioxygenase (IDO) Inhibitors
  申请人：ANDERSEN Raymond J.

  公开号：US20090042868A1

  公开（公告）日：2009-02-12

  Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.
• US7799776B2
  申请人：——

  公开号：US7799776B2

  公开（公告）日：2010-09-21